American Society of Clinical Oncology 47th Annual ... - ABCSG

Friday, June 3, 2011FRIDAYBrd. 7 H-RAS and PIK3CA mutations and response to cetuximab in head and necksquamous cell carcinoma (HNSCC). (Abstract #5513)T. Rampias, A. Giagini, K. Florou, P. Gouveris, E. Vaja, N. Haralambakis,P. Katsaounis, D. G. Pectasides, T. Economopoulos, A. PsyrriBrd. 8 Molecular prognostic prediction by support vector machine integratedapproach for local advanced nasopharyngeal carcinoma. (Abstract #5514)X. Wan, X. Wu, X. Fan, H. Cai, M. Chen, J. Xu, M. Hong, Q. LiuBrd. 9 Exosomal-miRNA profiles as diagnostic and prognostic biomarkers in headand neck squamous cell carcinoma (HNSCC). (Abstract #5515^)G. Rabinowits, C. G. Taylor, G. H. Kloecker, A. Patel, M. B. Hall, D. D. TaylorBrd. 10 Phase II study of chemoradiation plus bevacizumab (BV) forlocally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminaryclinical results of RTOG 0615. (Abstract #5516)N. Y. Lee, Q. Zhang, A. S. Garden, J. J. Kim, D. G. Pfister, J. Mechalakos, K. Hu,Q. Le, B. S. Glisson, A. T. Chan, K. AngBrd. 11 Phase II study of gefitinib adaptive dose escalation to skin toxicity inrecurrent and/or metastatic squamous cell carcinoma of the head and neck.(Abstract #5517)C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, A. Dekker,K. Stenson, E. A. Blair, O. I. Olopade, T. Y. Seiwert, E. E. Vokes, E. E. CohenBrd. 12 Phase I trial of bevacizumab combined with concurrent chemoradiation forsquamous cell carcinoma of the head and neck: Preliminary outcome results.(Abstract #5518)P. M. Harari, D. Khuntia, A. M. Traynor, T. Hoang, D. T. Yang, G. K. Hartig,T. M. McCulloch, R. Jeraj, M. J. Nyflot, P. A. Wiederholt, L. R. GentryBrd. 13 A randomized phase II trial of cetuximab-based induction chemotherapyfollowed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionatedradiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation withconcomitant boost (CetuxPX) in patients with locoregionally advanced headand neck cancer (HNC). (Abstract #5519)T. Y. Seiwert, D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama,M. Kocherginsky, V. M. Villaflor, M. Witt, R. Williams, A. Dekker, E. E. VokesBrd. 14 Randomized trial of a short course of erlotinib 150 to 300 mg daily prior tosurgery for squamous cell carcinomas of the head and neck (SCCHN) incurrent, former, and never smokers: Objective responses and clinicaloutcomes. (Abstract #5520)W. N. William Jr., R. S. Weber, J. Lee, J. Myers, L. E. Ginsberg, A. K. El-Naggar,E. M. Sturgis, A. L. Sabichi, M. S. Kies, E. Y. Hanna, A. C. Hessel, C. Lu, S. Y. Lai,R. Ayuste, S. M. Lippman, E. S. KimBrd. 15 A randomized phase III trial of magic mouthwash and sucralfate versusbenzydamine hydrochloride for prophylaxis of radiation-induced oralmucositis in head and neck cancer. (Abstract #5521)J. S. Kuk, S. Parpia, S. M. Sagar, T. Tsakiridis, D. Kim, D. I. Hodson, C. Zywine,J. R. WrightBrd. 16 Neurocognitive function (NCF) in patients (pts) treated withchemo/bioradiotherapy (C/B-RT) for head and neck cancers (HNC). (Abstract#5522)A. R. Abdul Razak, L. L. Siu, A. Chan, G. R. Pond, K. M. Tirona, E. X. Chen,A. J. Hope, J. Ringash, B. O’Sullivan, J. N. Waldron, K. Chan, H. K. Gan,L. J. BernsteinBrd. 17 Patient-reported fatigue in head and neck cancer survivors. (Abstract #5523)G. B. Gunn, T. R. Mendoza, A. S. Garden, X. S. Wang, W. H. Morrison, S. J. Frank,E. Y. Hanna, C. Lu, B. M. Beadle, K. Ang, C. S. Cleeland, D. I. Rosenthal72